Description: Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.
Home Page: www.neurogene.com
535 W 24th Street
New York,
NY
10011
United States
Phone:
(855) 508-3568
Officers
| Name | Title |
|---|---|
| Dr. Rachel L. McMinn Ph.D. | Founder, Executive Chair & CEO |
| Ms. Christine Mikail Cvijic J.D. | President, CFO & Corporate Secretary |
| Dr. Stuart Cobb Ph.D. | Chief Scientific Officer |
| Mr. Arvind Sreedharan | Senior Vice President of Business Operations |
| Ms. Donna M. Cochener-Metcalfe J.D. | Senior VP & General Counsel |
| Dr. Effie Albanis M.D. | Senior Vice President of Early Clinical & Translational Research |
| Dr. Andrew E. Mulberg CPI, FAAP, M.D. | Senior Vice President of Regulatory Affairs, Quality Assurance & Quality Control |
| Mr. Ricardo Jimenez | Senior Vice President of Technical Operations |
| Dr. Julie Jordan M.D. | Chief Medical Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.4145 |
| Price-to-Sales TTM: | 372.5719 |
| IPO Date: | 2014-03-07 |
| Fiscal Year End: | December |
| Full Time Employees: | 91 |